Page last updated: 2024-09-05

erlotinib hydrochloride and Auricular Cancer

erlotinib hydrochloride has been researched along with Auricular Cancer in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Halpin, C; Harris, GJ; McClatchey, AI; O'Donnell, CC; Plotkin, SR; Singh, MA1
Burns, SS; Bush, ML; Chang, LS; Davletova, S; Jacob, A; Oblinger, J; Welling, DB1

Other Studies

2 other study(ies) available for erlotinib hydrochloride and Auricular Cancer

ArticleYear
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.
    Nature clinical practice. Oncology, 2008, Volume: 5, Issue:8

    Topics: Audiometry, Pure-Tone; Auditory Threshold; Cochlear Implantation; Combined Modality Therapy; Ear Neoplasms; Erlotinib Hydrochloride; Hearing Loss, Sensorineural; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurofibromatosis 2; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Vestibular Diseases

2008
Treatment of vestibular schwannoma cells with ErbB inhibitors.
    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2012, Volume: 33, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Ear Neoplasms; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Lapatinib; Neuroma, Acoustic; Oncogene Proteins v-erbB; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Vestibular Nerve

2012